Citadel Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$222M Sell
241,714
-458,045
-65% -$464M 0.04% 410
2025
Q4
$752M Sell
699,759
-453,059
-39% -$433M 0.11% 112
2025
Q3
$880M Buy
1,152,818
+299,566
+35% +$223M 0.13% 90
2025
Q2
$665M Buy
853,252
+375,471
+79% +$292M 0.12% 111
2025
Q1
$395M Sell
477,781
-133,494
-22% -$111M 0.07% 180
2024
Q4
$472M Buy
611,275
+396,093
+184% +$328M 0.08% 160
2024
Q3
$191M Sell
215,182
-285,653
-57% -$257M 0.04% 378
2024
Q2
$453M Buy
500,835
+23,722
+5% +$19M 0.09% 138
2024
Q1
$371M Sell
477,113
-798,919
-63% -$569M 0.07% 190
2023
Q4
$744M Buy
1,276,032
+516,239
+68% +$301M 0.15% 67
2023
Q3
$408M Buy
759,793
+213,671
+39% +$110M 0.09% 130
2023
Q2
$256M Buy
546,122
+296,101
+118% +$124M 0.05% 237
2023
Q1
$85.9M Buy
250,021
+73,307
+41% +$24.7M 0.02% 707
2022
Q4
$64.6M Sell
176,714
-806,571
-82% -$286M 0.02% 932
2022
Q3
$318M Sell
983,285
-181,800
-16% -$57.6M 0.07% 177
2022
Q2
$378M Buy
1,165,085
+1,123,361
+2,692% +$337M 0.1% 127
2022
Q1
$11.9M Sell
41,724
-92,520
-69% -$23.8M ﹤0.01% 2690
2021
Q4
$37.1M Buy
134,244
+47,019
+54% +$11.9M 0.01% 1422
2021
Q3
$20.2M Sell
87,225
-401,002
-82% -$99M ﹤0.01% 1973
2021
Q2
$112M Buy
488,227
+376,546
+337% +$75.6M 0.03% 607
2021
Q1
$20.9M Sell
111,681
-2,013,741
-95% -$394M 0.01% 1913
2020
Q4
$359M Buy
2,125,422
+1,554,906
+273% +$232M 0.09% 127
2020
Q3
$84.4M Sell
570,516
-711,139
-55% -$110M 0.02% 558
2020
Q2
$210M Buy
1,281,655
+1,270,416
+11,304% +$195M 0.08% 166
2020
Q1
$1.56M Sell
11,239
-100,689
-90% -$13.8M ﹤0.01% 4549
2019
Q4
$14.7M Sell
111,928
-223,548
-67% -$25.9M 0.01% 1792
2019
Q3
$37.5M Buy
335,476
+34,070
+11% +$3.79M 0.02% 960
2019
Q2
$33.4M Sell
301,406
-3,372,002
-92% -$397M 0.02% 991
2019
Q1
$477M Buy
3,673,408
+3,307,234
+903% +$402M 0.24% 37
2018
Q4
$42.4M Buy
366,174
+46,164
+14% +$5.16M 0.02% 707
2018
Q3
$34.3M Sell
320,010
-16,231
-5% -$1.62M 0.02% 986
2018
Q2
$28.7M Buy
336,241
+172,940
+106% +$14.2M 0.01% 1027
2018
Q1
$12.6M Buy
163,301
+133,113
+441% +$10.7M 0.01% 1515
2017
Q4
$2.55M Sell
30,188
-87,004
-74% -$7.4M ﹤0.01% 3300
2017
Q3
$10M Sell
117,192
-798,906
-87% -$65.5M 0.01% 1601
2017
Q2
$75.4M Sell
916,098
-2,662,920
-74% -$217M 0.06% 325
2017
Q1
$301M Buy
3,579,018
+3,440,064
+2,476% +$276M 0.28% 36
2016
Q4
$10.2M Sell
138,954
-417,614
-75% -$31.1M 0.01% 1344
2016
Q3
$44.7M Sell
556,568
-1,013,313
-65% -$81.1M 0.04% 440
2016
Q2
$124M Buy
1,569,881
+398,634
+34% +$30M 0.14% 106
2016
Q1
$84.3M Sell
1,171,247
-548,888
-32% -$41.5M 0.11% 159
2015
Q4
$145M Sell
1,720,135
-2,694,303
-61% -$224M 0.16% 115
2015
Q3
$369M Buy
4,414,438
+2,869,107
+186% +$242M 0.35% 26
2015
Q2
$129M Buy
1,545,331
+505,941
+49% +$38.6M 0.11% 179
2015
Q1
$75.5M Sell
1,039,390
-75,396
-7% -$5.37M 0.07% 313
2014
Q4
$76.9M Buy
1,114,786
+1,071,150
+2,455% +$72.3M 0.08% 283
2014
Q3
$2.83M Sell
43,636
-344,948
-89% -$21.8M ﹤0.01% 2505
2014
Q2
$24.2M Buy
388,584
+161,927
+71% +$9.66M 0.03% 705
2014
Q1
$13.3M Buy
226,657
+174,495
+335% +$9.74M 0.02% 1092
2013
Q4
$2.66M Sell
52,162
-1,723,296
-97% -$86.3M ﹤0.01% 2251
2013
Q3
$89.4M Buy
1,775,458
+1,560,883
+727% +$81.7M 0.14% 135
2013
Q2
$10.5M Buy
+214,575
New +$11.7M 0.02% 1035

Other funds holding LLY

Citadel Advisors's LLY Position: Q1 2026 in Review

Citadel Advisors reduced its Eli Lilly (LLY) stake by 65% in Q1 2026, selling an estimated $464M and leaving 241,714 shares worth $222M. The position accounts for 0.04% of the portfolio, ranked #410.

Citadel Advisors first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $880M in Q3 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Citadel Advisors held 241,714 shares of Eli Lilly worth $222M as of Q1 2026.
  • Citadel Advisors sold 458,045 Eli Lilly shares in Q1 2026, an estimated $464M.
  • Eli Lilly made up 0.04% of Citadel Advisors's portfolio in Q1 2026, its #410 holding.
  • Citadel Advisors first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Citadel Advisors's Eli Lilly position peaked at $880M in Q3 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.